SCHEMBL23414575

SCHEMBL23414575

O=c1cc(C(F)(F)F)nc2cc(C(F)(F)F)ccn12

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP7 Q93009 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ ALPL P05186 2/20 0.41
▸ ALPI P09923 2/20 0.41
▸ GRIN1 Q05586 1/20 0.39
▸ GRIN2A Q12879 1/20 0.39
▸ KDM5B Q9UGL1 1/20 0.39
▸ DRD2 P14416 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ TRPA1 O75762 1/20 0.38
▸ MAT2A P31153 6/20 0.38
▸ KCNQ3 O43525 1/20 0.36
▸ KCNQ2 O43526 1/20 0.36
▸ PKM P14618 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23414865 0.87 ALDH1A1 (0.40) USP7ALDH1A1KDM4EALPLALPI
SCHEMBL23414762 0.84 ALDH1A1 (0.42) ALDH1A1KDM4EALPLALPIGRIN1
SCHEMBL23415012 0.83 ALDH1A1 (0.64) ALDH1A1KDM4EALPLALPIGRIN1
SCHEMBL23414795 0.83 ALDH1A1 (0.41) ALDH1A1KDM4EALPLALPIGRIN1
SCHEMBL23414701 0.83 ALDH1A1 (0.41) USP7ALDH1A1KDM4EALPLALPI
SCHEMBL23414793 0.83 GRIN1 (0.43) ALDH1A1KDM4EALPLALPIGRIN1
SCHEMBL23414978 0.79 ALPI (0.46) ALDH1A1KDM4EALPLALPIGRIN1
SCHEMBL23414823 0.79 ALDH1A1 (0.41) ALDH1A1KDM4EALPLALPIGRIN1
SCHEMBL23456452 0.79 ALDH1A1 (0.51) ALDH1A1KDM4EALPLALPIGRIN1
SCHEMBL23414770 0.79 ALPI (0.43) ALDH1A1KDM4EALPLALPIGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use AMGEN INC. (US) 2025-11-18 — — US disclosed
EP-4065579-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE Amgen Inc. (US) 2022-10-05 — — EP disclosed
US-20210171529-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE AMGEN INC. 2021-06-10 — — US disclosed
US-20210171529-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE AMGEN INC. 2021-06-10 — — US disclosed
WO-2021108404-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2021-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171529-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE SCD5, SCD, FADS2 USP7 2880/4885ALDH1A1 326/4885KDM4E 933/4885
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use SCD5, SCD, FADS2 USP7 2880/4885ALDH1A1 326/4885KDM4E 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback